1. Home
  2. STTK vs PRTH Comparison

STTK vs PRTH Comparison

Compare STTK & PRTH Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Shattuck Labs Inc.

STTK

Shattuck Labs Inc.

N/A

Current Price

$4.55

Market Cap

474.6M

Sector

Health Care

ML Signal

N/A

Logo Priority Technology Holdings Inc.

PRTH

Priority Technology Holdings Inc.

N/A

Current Price

$7.90

Market Cap

440.2M

Sector

Technology

ML Signal

N/A

Company Overview

Basic Information
Metric
STTK
PRTH
Founded
2016
2005
Country
United States
United States
Employees
N/A
N/A
Industry
Biotechnology: Pharmaceutical Preparations
EDP Services
Sector
Health Care
Technology
Exchange
Nasdaq
Nasdaq
Market Cap
474.6M
440.2M
IPO Year
2020
2016

Fundamental Metrics

Financial Performance
Metric
STTK
PRTH
Price
$4.55
$7.90
Analyst Decision
Strong Buy
Hold
Analyst Count
12
3
Target Price
★ $15.40
$8.03
AVG Volume (30 Days)
★ 841.6K
427.3K
Earning Date
11-05-2026
11-05-2026
Dividend Yield
N/A
N/A
EPS Growth
53.02
★ 319.35
EPS
N/A
★ 0.38
Revenue
★ $1,000,000.00
N/A
Revenue This Year
N/A
$8.54
Revenue Next Year
$14.28
$7.48
P/E Ratio
★ N/A
$20.79
Revenue Growth
N/A
★ N/A
52 Week Low
$1.89
$4.57
52 Week High
$8.33
$7.94

Technical Indicators

Market Signals
Indicator
STTK
PRTH
Relative Strength Index (RSI) 36.65 69.53
Support Level $4.38 $7.76
Resistance Level $7.66 $7.94
Average True Range (ATR) 0.39 0.03
MACD -0.02 -0.03
Stochastic Oscillator 13.92 55.00

Price Performance

Historical Comparison
STTK
PRTH

About STTK Shattuck Labs Inc.

Shattuck Labs Inc is a biotechnology company specializing in the development of potential treatments for inflammatory and immune-mediated diseases. It is developing a potentially first-in-class antibody for the treatment of inflammatory bowel disease (IBD) and other inflammatory and immune-mediated diseases. The company's expertise in protein engineering and the development of novel tumor necrosis factor (TNF) receptor therapeutics comes together in its main program, SL-325, which has the potential to be a first-in-class death receptor 3 (DR3) antagonist antibody. In addition, the company is developing SL-425, a half-life extended version of SL-325, and multiple other preclinical DR3-based bispecific antibodies, for the treatment of patients with IBD.

About PRTH Priority Technology Holdings Inc.

Priority Technology Holdings Inc is a fintech company that provides payment and banking-related solutions, including services for collecting, storing, lending, and transferring money for businesses. The company has three reportable segments: i) Merchant Solutions: Provides full-service acquiring and payment-enabled solutions for B2C transactions, ii) Payables: Provides AP automation solutions to corporations, software partners and FIs in addition to improving cash flows by providing instant access to working capital and iii) Treasury Solutions: Provides embedded finance and BaaS solutions to customers to modernize legacy platforms and accelerate software partners' strategies to monetize payments. The majority of the company's revenue is derived from the Merchant Solutions segment.

Share on Social Networks: